This trial looked at olaparib as a possible treatment for ovarian cancer in patients who had the BRCA gene mutation.
1 Primary · 8 Secondary · Reporting Duration: CA-125 performed at baseline then every 4 weeks. Radiologic scans performed at baseline then every 12 weeks up to 156 weeks, then every 24 weeks until objective radiological disease progression. Analysis of data assessed up to a maximum of 54 months.
450 Total Participants · 2 Treatment Groups
Primary Treatment: Olaparib 300mg tablets · Has Placebo Group · Phase 3
Age 18 - 130 · Female Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|Did not meet criteria||100.0%|